Drug companies urged to make more use of UK regulator's ''broader scope'' scientific advice
This article was originally published in SRA
Executive Summary
Pharmaceutical companies in the UK are missing a trick by failing to take advantage of the “broader scope” scientific advice service that is on offer from the Medicines and Healthcare products Regulatory Agency. The UK R&D-based pharma industry association, the ABPI, said in response that it would always encourage companies to get scientific advice from the MHRA and would work with the agency to raise awareness of the scheme within the industry.